NLRP3 inflammasome: a likely target for the treatment of allergic diseases
Dear Editor-in-Chief of Clinical and Experimental allergy:
Clinical and Experimental allergy publishes in-depth and cutting edge articles and evidence-based, balanced review on clinical or basic science of allergy and immunology. It is our great pleasure to propose our review to you.
Our group studies the allergic and autoimmune diseases. Here are representative articles in recent years as followed: xxxx (paper1 IF>10) xxxx (paper2 IF>10) xxxx
Currently, we wrote a review to summarize the recent research of the role of NLRP3 inflammasome, IL-1β, and IL-18 in allergic diseases. We believe this topic will be of interest to the readers of Clinical and Experimental allergy.
Much appreciation for you to offer some advice and take it into consideration.
Comments for Authors:
Comments for Authors:
Comprehensive review on the NLRP3 inflammasome as potential therapeutic target of allergic diseases, which may inspire more research using pharmacological inhibitors. Perhaps a table of current of the NLRP3 inflammasome would be included indicating the site of action on the different components and/or assembly of the complex.
The manuscript however needs a careful English editing.
Comments for Authors:
This work provides a comprehensive overview of our current knowledge of the potential role of the NLRP3 inflammasome in allergic inflammation. The authors have covered the evidence in a wide variety of allergic diseases, in both murine and human studies. My comments are listed below.
1. In the introduction, the authors use the abbreviation AD for allergic disease. This should be removed, as it is also the abbreviation for atopic dermatitis, and the abbreviation AD is more associated with that disease in particular.
2. Line 127, the authors use the word "proven". This should be changed to shown, or demonstrated.
3. The paragraph beginning at line 127 should be moved so that it is included under the section "The role of the NLRP3 inflammasomes, IL-1b, and IL-18 in asthma (starting at line 135).
4. The statement in line 134 should be moved to the introduction section.
5. Line 158, what is "IL-R1"?
6. Lines 212-214. The authors state "Exposure of Nlrp3(-/-) mice to particulate matter induced NLRP#-dependent..." This does not make sense, since the mice lacked NLRP3. Please revise this statement.
7. Line 232, please remove the statement "caused by HDM allergens". Atopic dermatitis is caused by many complex environmental and genetic factors, and symptoms are triggered by a variety of allergens, not just HDM.
8. Line 240, the word "chemokines" does not make sense here.
9. Line 243, please change "allergic disease" to "atopic dermatitis"
Thank you for submitting your manuscript to Clinical and Experimental Allergy. We have now received reports on your paper and the comments follow at the end for your attention.
In its present form the manuscript is not acceptable for publication. The editors would be prepared to consider a revised version if you believe you can provide a full and convincing response to the points raised. The opportunity to resubmit is, of course, subject to the usual refereeing process and does not guarantee acceptance since a revision may still not achieve a high enough priority to warrant publication.
Please study the comments carefully and amend the manuscript as appropriate. In your response, please ensure that you include all the comments by the reviewers with your point-by-point reply and indicate how you have revised your manuscript, clearly marking the changes in your manuscript (e.g. bold, italic or underlining). Upload the revised version of your manuscript online at https://mc.manuscriptcentral.com/cea and follow the instructions in the Author Centre, or use this link to create a revision *** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm.
【修回信件】Thank you for responding so quickly .We are glad to see our paper will be acceptable.Thanks a million for your hard work and timely reply,we will make further grammatical editing according tothe demand of the journal and reply in time.
Thank you very much for your consideration
The editors are pleased to confirm that your revised manuscript has been accepted for publication in Clinical & Experimental Allergy.
Your article cannot be published until the publisher has received the appropriate signed license agreement. Within the next few days the corresponding author will receive an email from Wiley’s Author Services system which will ask them to log in and will present them with the appropriate license for completion.
Effective with the 2016 volume, this journal will be published in an online-only format. Your accepted article will be published in 2016 and will therefore appear in the online edition. No printed edition will be published. All normal author benefits and services remain in place e.g. authors will continue to be able to order print reprints of articles if required. There will be no cost to authors for the publication of colour images in the online-only edition. Please see the author instructions for full details.